Biomm S.A.

Equities

BIOM3

BRBIOMACNOR2

Biotechnology & Medical Research

Market Closed - Sao Paulo Other stock markets 04:06:00 2024-04-29 pm EDT			5-day change	1st Jan Change
17.77 ^BRL	+10.99%		+8.62%	+207.44%

Apr. 18	Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	MT
Apr. 17	Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	CI

Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023

March 27, 2024 at 06:07 pm EDT

Biomm S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was BRL 118.19 million compared to BRL 104.95 million a year ago. Net loss was BRL 81.14 million compared to BRL 92.56 million a year ago.

Latest news about Biomm S.A.

Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	Apr. 17	MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	Apr. 17	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, A Stelara Biosimilar	23-06-16	CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-25	CI
Lupin Enters Partnership to Market Biosimilar Pegfilgrastim in Brazil	21-12-05	MT
Biomm S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days	21-05-27	CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications	21-04-07	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-26	CI
Bio-Thera Solutions Announces Licensing Agreement with Biomm S.A. to Distribute and Market BAT1706 in Brazil	20-12-17	CI
MannKind Corporation and BIOMM SA Announce that Afrezza® (insulin human) Inhalation Powder has Been Registered by the Brazilian Health Regulatory Agency	19-06-03	CI
MannKind Corporation and Biomm Enter into Distribution Agreement for Afrezza in Brazil	17-05-31	CI
Biomm S.A.(BOVESPA:BIOM3) added to Brazil Special Tag Along Stock Index	14-05-05	CI
Biomm S.A. announced that it has received BRL 10.81 million in funding from BDMGTEC SA, BNDES Participações S/A - BNDESPAR, Tekbio Fundo de Investimento em Participacoes, TMG Partners, LLC, TMG Servicos de Gestao Ltda., and other investors.	14-01-03	CI
Biomm S.A. announced that it has received funding from TMG Partners, LLC	13-12-30	CI

Chart Biomm S.A.

Duration

Period

More charts

Company Profile

Biomm SA, formerly Savicevic Participacoes SA, is a Brazil-based company primarily engaged in the biotechnology industry. The Company is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Companyâs technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Companyâs technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Companyâs subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOMM S.A.	+207.44%	310M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+2.62%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-9.19%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs